Journal
ONCOIMMUNOLOGY
Volume 1, Issue 8, Pages 1409-1410Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.21059
Keywords
NY-ESO-1; immunotherapy; sarcomas; synovial sarcoma; melanoma; cancer-testis antigen; diagnostic marker; clinical trial; therapeutic target; T-cell receptor
Categories
Ask authors/readers for more resources
NY-ESO-1 (CTAG 1B) is highly expressed in the majority of synovial sarcomas and myxoid/round cell liposarcomas as well as in a subset of melanomas, but only rarely in other mesenchymal tumors. This points to a potential for using NY-ESO-1 in the differential diagnosis of these lesions. Furthermore, promising results have been obtained in clinical trials testing NY-ESO-1-targeted immunotherapy in subsets of melanoma and synovial sarcoma patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available